CJC-1295 W/DAC – 5mg


2mg or 5mg per vial

Rated 5.0 out of 5
5.0 out of 5 stars (based on 1 review)
Very good0%
Add to Wishlist
Add to Wishlist

Leave A Review


Rated 5.0 out of 5
September 20, 2023

Accidentally ordered the wrong product, Joe fixed it in minutes and was very responsive via text on a Sat evening.


Response from NuScience Peptides

Happy to help and we try to be available all times within reason.


Molecular Formula


Molecular Weight3647.2
Monoisotopic Mass3645.0154843
Polar Area1540
Heavy Atom Count258
Hydrogen Bond Donor Count54
Hydrogen Bond Acceptor Count52
Rotatable Bond Count128
Physical AppearanceFine White Lyophilized Powder
StabilityLyophilized protein is to be stored at -20°C. It is recommended to aliquot the reconstituted (dissolved) protein into several discrete vials in order to avoid repeated freezing and thawing. Reconstituted protein can be stored at 4°C
PubChem LCSS

CJC-1295 WITH DAC Laboratory Chemical Safety Summary


InChIInChI=1S/C165H269N47O46/c1-22-87(15)130(209-137(233)92(20)185-148(244)116(76-127(225)226)196-136(232)89(17)183-138(234)99(168)73-95-44-48-97(217)49-45-95)160(256)204-115(74-94-36-25-24-26-37-94)154(250)211-132(93(21)216)162(258)195-108(54-57-123(171)221)145(241)205-120(80-215)158(254)200-114(75-96-46-50-98(218)51-47-96)153(249)192-105(43-35-66-182-165(177)178)141(237)191-102(40-28-31-62-167)146(242)208-129(86(13)14)159(255)202-109(68-81(3)4)147(243)184-90(18)135(231)189-106(52-55-121(169)219)143(239)198-112(71-84(9)10)151(247)206-118(78-213)156(252)186-91(19)134(230)188-103(41-33-64-180-163(173)174)140(236)190-101(39-27-30-61-166)142(238)197-111(70-83(7)8)150(246)199-110(69-82(5)6)149(245)194-107(53-56-122(170)220)144(240)201-117(77-128(227)228)155(251)210-131(88(16)23-2)161(257)203-113(72-85(11)12)152(248)207-119(79-214)157(253)193-104(42-34-65-181-164(175)176)139(235)187-100(133(172)229)38-29-32-63-179-124(222)60-67-212-125(223)58-59-126(212)224/h24-26, 36-37, 44-51, 58-59, 81-93, 99-120, 129-132, 213-218H, 22-23, 27-35, 38-43, 52-57, 60-80, 166-168H2, 1-21H3, (H2, 169, 219)(H2, 170, 220)(H2, 171, 221)(H2, 172, 229)(H, 179, 222)(H, 183, 234)(H, 184, 243)(H, 185, 244)(H, 186, 252)(H, 187, 235)(H, 188, 230)(H, 189, 231)(H, 190, 236)(H, 191, 237)(H, 192, 249)(H, 193, 253)(H, 194, 245)(H, 195, 258)(H, 196, 232)(H, 197, 238)(H, 198, 239)(H, 199, 246)(H, 200, 254)(H, 201, 240)(H, 202, 255)(H, 203, 257)(H, 204, 256)(H, 205, 241)(H, 206, 247)(H, 207, 248)(H, 208, 242)(H, 209, 233)(H, 210, 251)(H, 211, 250)(H, 225, 226)(H, 227, 228)(H4, 173, 174, 180)(H4, 175, 176, 181)(H4, 177, 178, 182)/t87-, 88-, 89+, 90-, 91-, 92-, 93+, 99-, 100-, 101-, 102-, 103-, 104-, 105-, 106-, 107-, 108-, 109-, 110-, 111-, 112-, 113-, 114-, 115-, 116-, 117-, 118-, 119-, 120-, 129-, 130-, 131-, 132-/m0/s1
Isomeric SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
IUPAC Name(3S)-4-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S, 3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S, 3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[3-(2, 5-dioxopyrrol-1-yl)propanoylamino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1, 5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid


NuScience Peptides sells research products only, they are not for human consumption.

Description – CJC-1295 W/DAC

CJC-1295 W/DAC is a synthetic peptide developed to be an analogy of growth hormone releasing hormone (GHRH)1. The 29 amino acid sequence is derived from GRF(1-29), a naturally occurring growth hormone releasing factor. CJC-1295 W/DAC is reported to be a potent agent for the stimulation of long-term growth hormone (GH) and IGF-1 release2. These biochemical actions have been shown to result in the promotion of lean body mass, enhanced strength, increased appetite, and an improved quality of sleep in animal test subjects3.

Product Comparison

Though CJC-1295 W/DAC is an analogy of GRF(1-29) and acts to release GH through a similar pathway, CJC-1295 W/DAC benefits from a much improved half-life relative to its native counterpart4. By existing in the bloodstream for long periods of time before degradation, CJC-1295 W/DAC is able to promote sustained GH release.

In spite of having a similar site of action, CJC-1295 W/DAC (and CJC-1295 no DAC) does not stimulate GH production using the same biochemical pathway as the popular GH secretagogue GHRP-65. In light of this observation, it has been possible for researchers to administrate CJC-1295 species and GHRP-6 concurrently in order to achieve an additive positive effect on GH release.

Drug Affinity Complex

The drug affinity complex (DAC) is a chemical group fixed to CJC-1295 that helps the peptide escape degradation by natural enzymes. By adding a component that gives CJC-1295 an affinity for albumin6, a naturally occurring protein in blood plasma, the peptide can achieve a much longer systemic half-life.

Preference for a long or short peptide half-life depends entirely on the research application of these agents.

NuScience Peptides sells research products only, they are not for human consumption.


CJC-1295 DAC; Sermonil; Sermonil-CJC-1295 DAC; Sermorelin Maleimidopropionyl; Modified GRF 1-29 with DAC, CJC-1295 W/DAC

Peer-Reviewed Sources:

  1. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
  2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
  3. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
  4. Jette, L., Leger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., … & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF) 1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology,146(7), 3052-3058.
  5. Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823.
  6. Beals, J. M., & Shanafelt, A. B. (2006). Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies, 3(1), 87-94.


Accurate research is our priority.

Same Day Shipping

Enjoy the convenience of receiving your order swiftly. We offer same-day shipping on all orders of in-stock items placed before 12:00 pm EST.

Dedicated Service

Our dedicated team is always at your service, Ready to assist you with any customer service requests you may have. We prioritize your satisfaction and aim to provide a seamless experience.

Free Shipping

To enhance your shopping experience, We offer free shipping on all orders totaling $125 or more. Rest assured, we've got you covered!

Purist Quality

We take pride in ensuring the utmost purity of our products. Every item we offer undergoes rigorous lab testing and is certified for the highest possible purity.

Shopping cart


No products in the cart.

Continue Shopping